To provide precision medicine for better cancer care, researchers must work on clinical
patient data, such as electronic medical records, physiological measurements, biochemistry …

Background Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoid
neoplasm among adults, and approximately 30–40% of patients will experience relapse …

DNA released from cells into the peripheral blood is known as cell-free DNA (cfDNA),
representing a promising noninvasive source of biomarkers that could be utilized to manage …

Background Patients with hematological cancer who experience relapse or progressive
disease often face yet another line of treatment and continued mortality risk that could …

Aim Our goal was to describe a precision medicine program in a regional academic hospital,
characterize features of included patients and present early data on clinical impact …

Precision oncology mainly relies on genetic and molecular patient profiling from high-
throughput sequencing data. The necessity to process and analyze large volumes of data …

Objectives To facilitate clinical implementation and research in precision oncology, notably
the pairing of patients, variants and treatments to identify candidates for clinical trials, we …

Splenic diffuse red pulp small B-cell lymphoma (SDRPL) is an extremely rare B-cell
lymphoma. The disease is typically indolent and treatment with splenectomy usually results …

Aim: To estimate current real-world costs of drugs and supportive care for the treatment of
multiple myeloma in a tax-based health system. Methods: Forty-one patients were included …

This thesis presents the work carried out from February 2017 to February 2021 at the
Department of Hematology, Aalborg University Hospital, and the Department of Clinical …